Kora Healthcare is accredited and certified to Good Manufacturing Practice, Good Distribution Practice, ISO 13485 and holds a manufacturing license and wholesale license for product portfolio assets and an importation license (DEL) in Canada. Kora Healthcare operates under a virtual manufacturing platform in that Kora Healthcare manufactures through an established network of contract manufacturing organisations and contract research organisations for development and commercial manufacturing.
Kora Healthcare operates broadly along two business models:
Our ‘Home Markets’ model supported by our established infrastructure across the UK, Ireland and Germany involves a mix of internally developed portfolio products and in-licensed products.
Our ‘International Markets’ model, by contrast, is focussed on developing long-term licensee’s and distributors with a like-minded therapy focus across global markets, supported by our internal team.
As a business we are resourced and optimally-sized to delivery continued growth for several years from our portfolio of currently marketed products, coupled with multiple opportunities for continued geographical expansion anticipating the delivery on our product development pipeline. Our development pipeline builds on existing therapeutic areas of focus and lifestyle brands of the patients and consumers we serve.
Our current priorities include optimising the international market expansion of ready –to-market, Magnaspartate and increasing the global footprint of brands such as Relactagel and Regelle. Together with our international focus, we continue to ensure launch readiness for our ever-evolving research, development and innovation pipeline.